Brief: Actinium Announces Completion Of Enrollment Of Second Dose Cohort In Actimab-A Venetoclax Combination Trial
25/03/2021 13:05
March 25 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES COMPLETION OF ENROLLMENT OF SECOND DOSE
COHORT IN ACTIMAB-A VENETOCLAX COMBINATION TRIAL FOR PATIENTS
WITH R/R AML
* ACTINIUM - PROOF-OF-CONCEPT PHASE 1 DATA EXPECTED IN
2H:2021
WILL EVALUATE SAFETY, RESPONSE RATES, MRD NEGATIVITY AND
CYTOGENETIC PROFILES
Source text for Eikon: ID:nPn2Dm5w1a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities